Industry CEOs Talk Drug Pricing, Value And The IRA
Value-based pricing for drugs remains largely a pipe dream in the US, industry leaders say, even as drug pricing pressure mounts.
You may also be interested in...
The combination of Astellas and Seagen's antibody-drug conjugate Padcev and Merck & Co's checkpoint inhibitor Keytruda has shown improvements in survival not previously achieved in a broad population of patients with advanced urothelial carcinoma.
There was lots of criticism of pharmacy benefit managers (and a fair amount aimed at pharmaceutical manufacturers) at the oversight hearing. However, Democrats may be more cautious about preserving the benefits PBMs provide versus the downsides in developing reforms.
The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.